Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622–4. https://doi.org/10.1002/nau.22609.

Article  PubMed  Google Scholar 

Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7. https://doi.org/10.1002/nau.22295.

Article  PubMed  Google Scholar 

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14. https://doi.org/10.1016/j.eururo.2006.09.019. discussion 14-5.

Article  PubMed  Google Scholar 

Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526-532.e18. https://doi.org/10.1016/j.urology.2009.06.096.

Article  PubMed  Google Scholar 

• Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–63. https://doi.org/10.1097/ju.0000000000000309. AUA/SUFU OAB Guideline reflecting relevant literature published through October 2018.

Article  PubMed  Google Scholar 

Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265(5):609–13.

Article  PubMed  CAS  Google Scholar 

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Intern Med. 2019;179(8):1084–93. https://doi.org/10.1001/jamainternmed.2019.0677.

Article  PubMed  PubMed Central  Google Scholar 

Peters KM, Killinger KA, Gilleran JP, Bartley J, Wolfert C, Boura JA. Predictors of reoperation after sacral neuromodulation: a single institution evaluation of over 400 patients. Neurourol Urodyn. 2017;36(2):354–9. https://doi.org/10.1002/nau.22929.

Article  PubMed  Google Scholar 

Rogers A, Bragg S, Ferrante K, Thenuwara C, Peterson DKL. Pivotal study of leadless tibial nerve stimulation with eCoin® for urgency urinary incontinence: an open-label, single arm trial. J Urol. 2021;206(2):399–408. https://doi.org/10.1097/ju.0000000000001733.

Article  PubMed  Google Scholar 

Chapple C, Sievert K-D, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56. https://doi.org/10.1016/j.eururo.2013.04.001.

Article  PubMed  CAS  Google Scholar 

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93. https://doi.org/10.1016/j.juro.2012.12.022.

Article  PubMed  CAS  Google Scholar 

Scheller EL, Krebsbach PH. Gene therapy: design and prospects for craniofacial regeneration. J Dent Res. 2009;88(7):585–96. https://doi.org/10.1177/0022034509337480.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53. https://doi.org/10.1038/s41392-021-00487-6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Anderson WF. Human gene therapy. Science. 1992;256(5058):808–13. https://doi.org/10.1126/science.1589762.

Article  PubMed  CAS  Google Scholar 

John Wiley and Sons LTD, Online. 2023. https://a873679.fmphost.com/fmi/webd/GTCT. Accessed 1/9/24

Cellular & Gene Prodcuts. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products (2023). Accessed 9/27/2023 2023.

Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706–18. https://doi.org/10.1056/NEJMoa2211644.

Article  PubMed  CAS  Google Scholar 

Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013–25. https://doi.org/10.1056/NEJMoa2113708.

Article  PubMed  CAS  Google Scholar 

Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284–93. https://doi.org/10.1016/s1474-4422(21)00001-6.

Article  PubMed  CAS  Google Scholar 

Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 2019;126(9):1273–85. https://doi.org/10.1016/j.ophtha.2019.06.017.

Article  PubMed  Google Scholar 

Guide SV, Gonzalez ME, Bagci IS, Agostini B, Chen H, Feeney G, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387(24):2211–9. https://doi.org/10.1056/NEJMoa2206663.

Article  PubMed  CAS  Google Scholar 

• Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107–17. https://doi.org/10.1016/s1470-2045(20)30540-4. First FDA-approved gene therapy in the genitourinary system demonstrating reduction in recurrence of bladder cancer after instillation of adenovirus containing interferon alpha-2b.

Keay SK, Birder LA, Chai TC. Evidence for bladder urothelial pathophysiology in functional bladder disorders. Biomed Res Int. 2014;2014:865463. https://doi.org/10.1155/2014/865463.

Article  PubMed  PubMed Central  Google Scholar 

Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50(6A Suppl):57–67. https://doi.org/10.1016/s0090-4295(97)00591-8. discussion 8-73.

Article  PubMed  CAS  Google Scholar 

Al-Ghazo MA, Ghalayini IF, Al-Azab R, Hani OB, Matani YS, Haddad Y. Urodynamic detrusor overactivity in patients with overactive bladder symptoms. Int Neurourol J. 2011;15(1):48–54. https://doi.org/10.5213/inj.2011.15.1.48.

Article  PubMed  PubMed Central  Google Scholar 

Burgers R, de Jong TP, Visser M, Di Lorenzo C, Dijkgraaf MG, Benninga MA. Functional defecation disorders in children with lower urinary tract symptoms. J Urol. 2013;189(5):1886–91. https://doi.org/10.1016/j.juro.2012.10.064.

Article  PubMed  Google Scholar 

Carter D, Beer-Gabel M. Lower urinary tract symptoms in chronically constipated women. Int Urogynecol J. 2012;23(12):1785–9. https://doi.org/10.1007/s00192-012-1812-1.

Article  PubMed  Google Scholar 

Wu C, Sui GP, Fry CH. Purinergic regulation of guinea pig suburothelial myofibroblasts. J Physiol. 2004;559(Pt 1):231–43. https://doi.org/10.1113/jphysiol.2004.067934.

Article  PubMed  PubMed Central  CAS  Google Scholar 

O’Reilly BA, Kosaka AH, Knight GF, Chang TK, Ford AP, Rymer JM, et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol. 2002;167(1):157–64.

Article  PubMed  CAS  Google Scholar 

Ray FR, Moore KH, Hansen MA, Barden JA. Loss of purinergic P2X receptor innervation in human detrusor and subepithelium from adults with sensory urgency. Cell Tissue Res. 2003;314(3):351–9. https://doi.org/10.1007/s00441-003-0788-z.

Article  PubMed  CAS  Google Scholar 

Fry CH, Ikeda Y, Harvey R, Wu C, Sui GP. Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology. 2004;63(3 Suppl 1):24–31. https://doi.org/10.1016/j.urology.2003.10.031.

Article  PubMed  Google Scholar 

Neuhaus J, Pfeiffer F, Wolburg H, Horn L-C, Dorschner W. Alterations in connexin expression in the bladder of patients with urge symptoms. BJU Int. 2005;96(4):670–6. https://doi.org/10.1111/j.1464-410X.2005.05703.x.

Article  PubMed  CAS  Google Scholar 

Maake C, Landman M, Wang X, Schmid DM, Ziegler U, John H. Expression of smoothelin in the normal and the overactive human bladder. J Urol. 2006;175(3 Pt 1):1152–7. https://doi.org/10.1016/s0022-5347(05)00315-0.

Article  PubMed  CAS  Google Scholar 

Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84(3):935–86. https://doi.org/10.1152/physrev.00038.2003.

Article  PubMed  CAS  Google Scholar 

Hristov KL, Afeli SA, Parajuli SP, Cheng Q, Rovner ES, Petkov GV. Neurogenic detrusor overactivity is associated with decreased expression and function of the large conductance voltage- and Ca(2+)-activated K(+) channels. PLoS One. 2013;8(7):e68052. https://doi.org/10.1371/journal.pone.0068052. Detrusor overactivity is associated with decreased BK channel expression.

Mukerji G, Yiangou Y, Corcoran SL, Selmer IS, Smith GD, Benham CD, et al. Cool and menthol receptor TRPM8 in human urinary bladder disorders and clinical correlations. BMC Urol. 2006;6:6. https://doi.org/10.1186/1471-2490-6-6.

Article  PubMed  PubMed Central  CAS